

**May 30, 2019**

To,  
Department of Corporate Services  
**BSE Limited**  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001  
Scrip Code: **BSE - 524500**

To,  
Corporate Listing Department  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051  
Scrip Code: **NSE - KILITCH**

Dear Sirs,

**Sub: Press Release**

We are pleased to enclosed herewith our Press Release relating to Financial Results for Financial Year 2018-19.

This is for your information and record.

Thanking you,

Yours Faithfully,  
For **Kilitch Drugs (India) Limited**



**Mukund Mehta**  
**Managing Director**  
**DIN:00147876**



**Encl: as above**





## **Kilitch Drugs (India) records 42.68% standalone growth in Q4FY19**

*Consolidated Net Sales up (Y-o-Y) by Rs. 31.49 crore  
Registers a consolidated net profit after tax of Rs. 3.83 crore  
Consolidated EPS for the year stood at Rs. 2.61*

- **BSE Code: 524500 NSE Code: KILITCH**
- **Standalone Sales / Income from operations at Rs. 22.33 crore, a growth of 42.68 % over same quarter last year.**
- **Headquartered in Mumbai (India), with footprints in Indian, African, East Asian and European markets**
- **Product profile comprises injectables and OTC brands across parenteral and nasal products, oral, effervescent, nutritional products, medical devices and cosmetic and herbal products**
- **Exhaustive experience in fast growing West and East African markets with more than 275 products registered and another 250 under registration**

**Mumbai, May 30, 2019:** The Board of Directors of Kilitch Drugs India Limited announced its standalone along with consolidated results for the fourth quarter and year ended March 31, 2019 following its approval by the Board of Directors in a meeting held in Mumbai today.

For the fourth quarter ended March 31, 2019, Standalone revenue from operations was at Rs 22.33 crore as against Rs 15.70 crore, recording an increase of 42.68%. Standalone Net Profit after tax was at Rs. 2.65 crore for the quarter ended March 31, 2019 as compared to Rs 2.28 crore in the previous corresponding quarter. EBITDA stood at Rs. 3.53 crore in the quarter ended March 31, 2019 as against Rs. 3.05 crore in the previous corresponding quarter.

For the year ended March 31, 2019, Kilitch Drugs (India) Ltd published its consolidated revenue of Rs. 86.49 crore as against Rs. 53.88 crore, recording an increase of 60.52% over the previous corresponding period. Consolidated Net Profit was at Rs.3.82 crore for the year ended March 31, 2019, as against Rs 5.15 crore in the previous year. Consolidated EBITDA for the fiscal year ended March 31, 2019 stood at Rs. 8.58 crore as against Rs. 6.11 crore in the previous corresponding period.



Kilitch Drugs (India) Ltd.

The Board of Directors have recommended a dividend of Rs.0.50 per share of face value Rs 10, subject to shareholders approval.

*“Our growth momentum continued during the financial year despite the challenging business environment across different markets. During the year, we took a strategic step of building our new facility in Ethiopia. We believe this will help accelerate the growth of the overall organization”, said **Mr. Mukund Mehta, Managing Director, Kilitch Drugs (India) Ltd***

***About Kilitch Drugs (India) Limited***

Kilitch Drugs was incorporated in May 1992 as a public limited company. The company went public in February 1994 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of injectables. The company believes Africa is the pharma market for next decade and working towards that goal by registering as many products possible to have a proper inroad in various east and west African countries.

For Information please contact [info@kilitch.com](mailto:info@kilitch.com) or visit [www.kilitch.com](http://www.kilitch.com)